JP2011512364A - 治療用ペプチド - Google Patents
治療用ペプチド Download PDFInfo
- Publication number
- JP2011512364A JP2011512364A JP2010547006A JP2010547006A JP2011512364A JP 2011512364 A JP2011512364 A JP 2011512364A JP 2010547006 A JP2010547006 A JP 2010547006A JP 2010547006 A JP2010547006 A JP 2010547006A JP 2011512364 A JP2011512364 A JP 2011512364A
- Authority
- JP
- Japan
- Prior art keywords
- dendrimer
- amino acid
- polypeptide
- seq
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008900848A AU2008900848A0 (en) | 2008-02-22 | Therapeutic peptides | |
| PCT/AU2009/000201 WO2009103127A1 (en) | 2008-02-22 | 2009-02-23 | Therapeutic peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011512364A true JP2011512364A (ja) | 2011-04-21 |
| JP2011512364A5 JP2011512364A5 (cg-RX-API-DMAC10.html) | 2013-05-02 |
Family
ID=40985007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547006A Pending JP2011512364A (ja) | 2008-02-22 | 2009-02-23 | 治療用ペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110105408A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2254901A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2011512364A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2009217237A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2009103127A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010215086A1 (en) * | 2009-02-23 | 2011-09-08 | Inter-K Pty Limited | Inhibition of multiple cell activation pathways |
| EP3228714B1 (en) | 2010-12-14 | 2019-03-27 | Stichting Katholieke Universiteit | Chemiluminescence-based haemostasis assay |
| CN104271590B (zh) * | 2012-01-24 | 2018-06-05 | Inter-K私人有限公司 | 用于癌治疗的肽剂 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023476A1 (en) * | 1998-10-16 | 2000-04-27 | Otsuka Pharmaceutical Co., Ltd. | Neovascular-specific peptides |
| WO2005037308A1 (en) * | 2003-10-17 | 2005-04-28 | Inter-K Pty Limited | Methods and agents for the treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4177263A (en) * | 1972-02-28 | 1979-12-04 | Research Corporation | Anti-animal tumor method |
| US5962643A (en) * | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
| US6514745B1 (en) * | 1993-07-19 | 2003-02-04 | The Regents Of The University Of California | Oncoprotein protein kinase |
| US5807746A (en) * | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
| US6495518B1 (en) * | 1994-06-13 | 2002-12-17 | Vanderbilt University | Method for importing biologically active molecules into cells |
| US5877282A (en) * | 1996-09-20 | 1999-03-02 | Bristol-Myers Squibb Company | Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
| US6495514B1 (en) * | 1998-01-21 | 2002-12-17 | Mercer University | Method for reducing inflammation and inducing an analgesic effect and compounds thereof |
| US6248558B1 (en) * | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
| ATE385503T1 (de) * | 1999-06-28 | 2008-02-15 | Inter K Pty Ltd | Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien |
| US6312956B1 (en) * | 1999-10-01 | 2001-11-06 | Vanderbilt University | Nuclear targeted peptide nucleic acid oligomer |
| US6471968B1 (en) * | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
| AUPR230500A0 (en) * | 2000-12-22 | 2001-01-25 | University Of Newcastle Research Associates Limited, The | A method of modulating map kinase mediated cellular activity and agents useful in same |
| US20060257359A1 (en) * | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| US20060204443A1 (en) * | 2005-03-11 | 2006-09-14 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for tumor treatment using dendrimer conjugates |
-
2009
- 2009-02-23 US US12/735,869 patent/US20110105408A1/en not_active Abandoned
- 2009-02-23 WO PCT/AU2009/000201 patent/WO2009103127A1/en not_active Ceased
- 2009-02-23 EP EP09713470A patent/EP2254901A4/en active Pending
- 2009-02-23 JP JP2010547006A patent/JP2011512364A/ja active Pending
- 2009-02-23 AU AU2009217237A patent/AU2009217237A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023476A1 (en) * | 1998-10-16 | 2000-04-27 | Otsuka Pharmaceutical Co., Ltd. | Neovascular-specific peptides |
| WO2005037308A1 (en) * | 2003-10-17 | 2005-04-28 | Inter-K Pty Limited | Methods and agents for the treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009217237A1 (en) | 2009-08-27 |
| EP2254901A1 (en) | 2010-12-01 |
| WO2009103127A1 (en) | 2009-08-27 |
| EP2254901A4 (en) | 2012-02-22 |
| US20110105408A1 (en) | 2011-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008273813B2 (en) | Bioactive peptides and method of using same | |
| IL223678A (en) | Immunosuppressive Modulation Compounds | |
| US9757473B2 (en) | Cell-penetrating peptide and conjugate comprising same | |
| CN102470156A (zh) | 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途 | |
| CN104271590A (zh) | 用于癌治疗的肽剂 | |
| US20120277161A1 (en) | Inhibition of multiple cell activation pathways | |
| WO2018166119A1 (zh) | 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用 | |
| US11033609B2 (en) | Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis | |
| US9765113B2 (en) | Methods and agents for the treatment of cancer | |
| JP2012518602A (ja) | 複数の細胞活性化経路の阻害 | |
| US20110105408A1 (en) | Therapeutic peptides | |
| US10907212B2 (en) | Inhibitors of cell adhesion | |
| CA3168943A1 (en) | Ligand-mediated delivery of therapeutic proteins and the uses thereof | |
| KR101721733B1 (ko) | 혈관신생촉진용 펩타이드 및 이의 용도 | |
| WO2018109771A1 (en) | Fusion proteins for treatment of cancer | |
| WO2021098996A1 (en) | Oligopeptides that inhibit angiogenesis and vascular function | |
| WO2016097753A1 (en) | Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis | |
| CN111333699A (zh) | 一种多肽或其衍生物及其在制备防治肿瘤的药物中的应用 | |
| US11541101B1 (en) | LEMD3 antagonizes TGF-beta-driven Smad2/3 transcription in a stiffness-dependent fashion in both the nucleus and cytosol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120223 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130424 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130620 |
|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A072 Effective date: 20130827 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130910 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131209 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140213 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140314 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140819 |